查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984104

In Silico藥物發現市場：2026-2032年全球市場預測（按技術平台、治療領域、分子模式、應用、最終用戶和部署模式分類）

In-Silico Drug Discovery Market by Technology Platform, Therapeutic Area, Molecule Modality, Application, End User, Deployment Model - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，In Silico藥物發現市場價值將達到 30.3 億美元，到 2026 年將成長到 33.1 億美元，到 2032 年將達到 57.5 億美元，複合年成長率為 9.58%。

主要市場統計數據
基準年 2025 30.3億美元
預計年份：2026年 33.1億美元
預測年份 2032 57.5億美元
複合年成長率 (%) 9.58%

電腦輔助藥物發現作為一種組織能力，具有戰略重要性，它整合了資料科學、實驗檢驗和營運管治。

In Silico輔助藥物發現正從一種簡單的輔助手段發展成為現代轉化研究的核心支柱，它融合了計算、數據和專業知識，加速藥物發現生命週期中的決策過程。本文不僅將該領域定位為一套工具，更將其視為一種綜合方法，能夠縮短研發週期，提高假設質量，並在研發早期階段做出更可靠的「做/不做」決策。此外，本文也將電腦輔助方法置於更廣泛的研發策略框架下，強調了協調實驗檢驗、法規要求和商業性需求的重要性日益凸顯，而非可有可無。

計算方法、基礎設施規模和夥伴關係模式的進步如何從根本上重塑藥物發現策略和藥物發現研究的管治。

In Silico藥物發現領域的格局正經歷著幾項變革性的轉變，這些轉變從根本上改變了成功的定義及其實現方式。首先，調查方法的融合正在帶來更可靠的結果。基於物理的分子模擬正擴大與機器學習模型相結合，這些模型能夠從公共和專有資料集中學習，從而形成混合方法，既能捕捉機制層面的洞見，又能將預測擴展到大規模化合物庫。這種整合需要一種新的跨學科人才團隊和工作流程，以協調不同的不確定性因素和檢驗標準。

本研究評估了 2025 年美國實施的關稅措施對電腦輔助藥物發現操作中的採購、供應鏈韌性和實施決策的連鎖影響。

2025年的政策環境，特別是美國發起的關稅，將對In Silico藥物發現生態系統產生多方面的影響，而不僅限於直接採購成本。關稅波動將影響關鍵硬體組件（例如GPU和專用加速器）的可用性和價格，這些組件對於高通量分子模擬和深度學習模型訓練至關重要。隨著進口關稅的提高，採購週期將會延長，從而改變資本預算決策，促使各機構重新評估其運算基礎設施的更新週期，並優先考慮工作負載整合和雲端遷移，以降低初始投資風險。

可操作的細分情報，用於繪製平台架構、應用程式需求、部署偏好、最終用戶優先順序和治療領域限制，以便進行有針對性的功能開發。

了解細分市場對於協調技術投資和組織優先事項與多樣化的工作流程和特定使用者需求至關重要。必須注意基於技術平台的不同角色，例如計算化學和生物資訊學、高效能運算、機器學習和人工智慧以及分子建模。每個平台細分市場都需要其自身合適的資料工程流程、檢驗框架和人才庫。整合這些平台為混合方法創造了機會，這些方法將基於機制的模擬與數據驅動的預測相結合。

美洲、歐洲、中東和非洲以及亞太地區的能力模式和戰略考量決定了實施路徑和夥伴關係模式。

區域環境塑造了企業能力的引入和擴展方式，進而影響人才獲取、監管預期和夥伴關係生態系統。美洲地區聚集了許多一體化生物製藥公司，擁有充滿活力的Start-Ups生態系統，有利於快速原型製作、便利的創業投資以及與臨床網路的深度合作。這些條件支持雄心勃勃的內部平台和商業性夥伴關係，但同時也要求企業密切關注智慧財產權策略並遵守不斷變化的監管準則。

差異化的技術能力、夥伴關係模式和檢驗方法如何塑造電腦輔助藥物發現領域的競爭定位和長期商業性關係。

In Silico藥物發現領域的競爭動態並非由單一供應商主導，而是由專業技術供應商、平台整合商和生物製藥應用商組成的生態系統所構成，形成一個模組化的價值鏈。技術供應商透過專有演算法、精心設計的訓練資料集以及與實驗室自動化系統和電子實驗記錄本（ELN）系統的整合能力來脫穎而出。一些公司專注於基於物理的模擬和分子建模，而其他公司則強調生成式化學和深度學習方法，從而在藥物發現過程的每個階段創造獨特的價值提案。

行業領導者應採取的具體策略和營運重點，以將電腦輔助藥物發現從試點階段擴展到檢驗和運行的藥物發現流程。

產業領導者應採取持續的策略和營運措施，將計算科學的潛力轉化為永續的專案成果。首先，建立將計算科學目標與治療目標和產品組合目標相銜接的管治，確保模型輸出能夠直接反映在臨床前決策中，並確保各團隊的評估指標標準化。這種協調一致將減少從先導計畫過渡到實用化流程時的阻力，並明確投資重點。

一項透明的混合方法研究通訊協定，結合了專家直接參與、二手文獻整合以及多源資料檢驗，以確保獲得穩健且可操作的見解。

本分析的研究方法結合了質性專家對話、結構化二手證據整合以及嚴格的資料檢驗通訊協定。關鍵資訊是透過與計算化學、機器學習、高效能運算操作和監管領域的專家進行半結構化訪談收集的，從而直接洞察了實踐中觀察到的操作挑戰、應用障礙和成功因素。整合這些對話揭示了不同組織類型中通用主題和多樣化實踐。

綜合結論強調，管治、可重複性和實施的柔軟性對於從基於計算化學的藥物發現計劃中實現永續價值至關重要。

總之，In Silico藥物發現正日益成熟，成為一項戰略能力，需要精心設計的組織架構、靈活的基礎設施和嚴謹的檢驗方法才能實現永續的轉換價值。混合計算方法、不斷演進的夥伴關係模式以及區域部署的實際情況相互作用，既帶來了機遇，也帶來了營運上的複雜性，領導者必須積極應對。那些能夠將技術選擇與治療重點相結合、將可重複性和可解釋性融入工作流程並採取穩健的採購和部署策略的組織，將獲得最大的利益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按技術平台In Silico藥物發現市場

  • 計算化學與生物資訊學
  • 高效能運算
  • 機器學習/人工智慧
  • 分子建模

第9章：In Silico藥物發現市場：依治療領域分類

  • 循環系統
  • 中樞神經系統
  • 感染疾病
  • 腫瘤學

第10章：In Silico藥物發現市場

  • 低分子化合物
  • 生物製藥
    • 單株抗體
    • 雙特異性抗體
  • 胜肽
    • 線性胜肽
    • 環肽
  • 寡核苷酸和RNA
    • siRNA
    • mRNA治療藥物

第11章：In Silico藥物發現市場：按應用領域分類

  • ADMET預測
    • 吸收預測
    • 分佈預測
    • 排泄預測
    • 代謝預測
    • 毒性預測
  • 先導化合物的鑑定與最佳化
    • De Novo 設計
    • 基於片段的最佳化
  • 藥物藥物動力學模型
  • 目標識別與檢驗
  • 虛擬篩檢
    • 基於配體的虛擬篩檢
    • 基於結構的虛擬篩檢

第12章：In Silico藥物發現市場：依最終使用者分類

  • 學術和研究機構
  • 合約研究機構
  • 製藥和生物技術公司

第13章：In Silico藥物發現市場：依開發模式分類

  • 基於雲端的
  • 現場

第14章：In Silico藥物發現市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：In Silico藥物發現市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：In Silico藥物發現市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國In Silico藥物發現市場

第18章：中國In Silico藥物發現市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Charles River Laboratories International, Inc.
  • Schrodinger Inc.
  • Certara, Inc.
  • XtalPi by Shenzhen Jingtai Technology Co., Ltd
  • InSilico Medicine
  • Dassault Systemes SE
  • BenevolentAI
  • Recursion Pharmaceuticals
  • Evotec SE
  • Iktos SA
  • WuXi AppTec
  • Envisagenics
  • AbCellera Biologics Inc.
  • Abzena Ltd.
  • Aragen Life Sciences Pvt. Ltd.
  • AstraZeneca PLC
  • BioDuro LLC
  • BioNTech SE
  • Chemical Computing Group ULC
  • ChemPartner PharmaTech Co Ltd
  • Creative Biostructure
  • Curia Global Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenScript Biotech Corporation
  • GlaxoSmithKline plc
  • Ligand Pharmaceuticals Incorporated
  • Merck & Co.
  • Novartis AG
  • Sanofi Group
  • Selvita SA
  • Simulations Plus, Inc.
  • Sygnature Discovery
  • Valo Health, Inc.
  • Viva Biotech Holding Group
Product Code: MRR-2E76C3E47FCA

The In-Silico Drug Discovery Market was valued at USD 3.03 billion in 2025 and is projected to grow to USD 3.31 billion in 2026, with a CAGR of 9.58%, reaching USD 5.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.03 billion
Estimated Year [2026] USD 3.31 billion
Forecast Year [2032] USD 5.75 billion
CAGR (%) 9.58%

Framing the strategic importance of computational drug discovery as an organizational competency that integrates data science, experimental validation, and operational governance

In-silico drug discovery is transitioning from a complementary capability to a central pillar of modern translational research, where computation, data, and domain expertise converge to accelerate decision-making across the discovery lifecycle. This introduction frames the discipline not merely as a set of tools but as an integrated approach that reduces cycle times, elevates hypothesis quality, and enables higher-confidence go/no-go decisions earlier in development. It also situates computational approaches within broader R&D strategies, where alignment with experimental validation, regulatory expectations, and commercial imperatives is increasingly mandatory rather than optional.

The contemporary landscape is characterized by multiple interacting forces: exponential growth in biological data, maturation of machine learning methods tailored to molecular science, and the commoditization of computational capacity through cloud and on-premise environments. These forces have produced an environment in which teams can explore chemical space more systematically, predict ADMET attributes with greater nuance, and triage targets through integrated systems biology perspectives. Consequently, leaders must think beyond isolated proof-of-concept pilots and toward scalable pipelines that embed reproducibility, explainability, and cross-functional handoffs between computational scientists, medicinal chemists, and translational biologists.

Furthermore, the rise of collaborative business models-ranging from vendor partnerships to consortium science-has enabled smaller organizations to access capabilities formerly exclusive to large pharmaceutical companies. This rebalancing of capability access places a premium on orchestration skills: the ability to coordinate data provenance, harmonize modeling outputs, and integrate external service providers in ways that preserve intellectual property while maximizing innovation velocity. In sum, the introduction underscores that in-silico drug discovery is now an organizational competency that requires strategy, governance, and investment in people and infrastructure to deliver sustained value.

How converging advances in computational methods, infrastructure scale, and partnership models are fundamentally reshaping discovery strategies and governance in drug research

The landscape of in-silico drug discovery is being reshaped by several transformative shifts that collectively change what success looks like and how it is achieved. First, methodological convergence is driving more robust outputs: physics-informed molecular simulation is increasingly combined with machine learning models that learn from both public and proprietary datasets, producing hybrid approaches that capture mechanistic insight while scaling predictions across large compound libraries. This convergence demands new interdisciplinary talent profiles and workflows that can reconcile different sources of uncertainty and validation criteria.

Second, infrastructure maturation is enabling operational scalability. Access to high-performance computing resources, whether on-premise clusters or cloud instances optimized for GPU workloads, permits the routine execution of computationally intensive simulations alongside rapid inference pipelines. As a result, organizations are shifting from isolated algorithmic experiments toward continuous integration of predictive models into discovery pipelines, with automated data curation and monitoring to ensure reproducibility.

Third, partnership models are evolving. Strategic alliances between technology vendors, contract research organizations, and biopharma companies are forming to pool domain knowledge, share curated datasets under secure governance, and accelerate target validation. These collaborations are complemented by an ecosystem of specialized service providers who offer modular capabilities-for example, de novo molecular design engines or ligand- and structure-based virtual screening platforms-enabling adopters to compose tailored toolchains.

Finally, regulatory and ethical considerations are becoming central to technology adoption. Expectations around model interpretability, data provenance, and reproducibility are increasing from both internal governance bodies and external stakeholders. Companies that proactively embed auditability and explainability into their computational workflows are better positioned to navigate regulatory scrutiny and build trust with clinical and commercial partners. Taken together, these shifts are not incremental; they reconfigure talent, technology, and governance in ways that favor organizations able to operationalize complex, hybrid computational strategies.

Evaluating how United States tariff measures enacted in 2025 cascade through procurement, supply chain resilience, and deployment decisions across computational drug discovery operations

The policy environment in 2025, including tariff actions originating from the United States, exerts multifaceted effects on in-silico drug discovery ecosystems that extend beyond immediate procurement costs. Tariff shifts influence the availability and pricing of critical hardware components such as GPUs and specialized accelerators, which are essential for high-throughput molecular simulation and deep learning model training. When import duties rise, procurement cycles elongate and capital budgeting decisions shift, prompting organizations to reevaluate refresh cadences for compute infrastructure and to prioritize workload consolidation or cloud migration to mitigate upfront capital exposure.

In addition to hardware considerations, tariffs affect the global software and service supply chain. Many specialized service providers and OEMs operate cross-border manufacturing and support networks; increased trade frictions complicate maintenance contracts, spare parts logistics, and multi-region service level agreements. These operational frictions can lead to higher total cost of ownership for on-premise systems and incentivize a rebalancing toward cloud-based deployments in jurisdictions with more favorable trade arrangements or local data center presence.

Strategically, tariff-driven uncertainty accelerates supply chain diversification and regionalization strategies. Organizations may pursue vendor redundancy, cultivate local partnerships with service providers and contract research organizations, or invest in domestic capacity for key components. Such moves can increase resilience but also raise near-term integration and validation burdens as teams adapt to heterogeneous toolchains and differing support models. Furthermore, tariffs can indirectly influence talent mobility and vendor negotiation dynamics, as suppliers seek to offset margin pressure through service bundling or altered licensing terms.

From a programmatic perspective, tariff impacts underscore the importance of flexible deployment architectures. Hybrid models that combine cloud bursting for peak workloads with on-premise platforms for sensitive or latency-dependent tasks enable teams to respond to both cost volatility and data sovereignty requirements. Decision-makers should therefore incorporate trade-policy scenarios into procurement planning and resilience assessments to ensure computational continuity while managing capital and operating expenditures prudently.

Actionable segmentation intelligence mapping platform architectures, application needs, deployment preferences, end-user priorities, and therapeutic area constraints for targeted capability building

Understanding segmentation is critical to aligning technical investments and organizational priorities with the specific demands of different workflows and users. Based on Technology Platform, attention should be paid to the distinct roles of Computational Chemistry and Bioinformatics versus High Performance Computing, Machine Learning and AI, and Molecular Modeling. Each platform segment requires tailored data engineering pipelines, validation frameworks, and talent mixes, and integrating these platforms creates opportunities for hybrid approaches that blend mechanistic simulation with data-driven prediction.

Based on Application, it is important to distinguish the varied requirements across ADMET Prediction, Lead Identification and Optimization, Pharmacokinetics Modeling, Target Identification and Validation, and Virtual Screening. ADMET Prediction itself decomposes into absorption prediction, distribution prediction, excretion prediction, metabolism prediction, and toxicity prediction, each demanding specialized datasets and domain-specific interpretability. Lead Identification and Optimization encompasses de novo design and fragment-based optimization approaches, which differ in their dependency on generative models versus expert-driven medicinal chemistry heuristics. Virtual Screening bifurcates into ligand-based virtual screening and structure-based virtual screening, with the former favoring cheminformatics and fingerprinting strategies and the latter relying on structural bioinformatics and docking accuracy.

Based on End User, differentiation among Academic and Research Institutes, Contract Research Organizations, and Pharmaceutical and Biotechnology Companies highlights divergent priorities: academic groups may prioritize methodological innovation and open science, contract research organizations emphasize reproducibility and throughput for client deliverables, and industry sponsors focus on regulatory robustness, IP protection, and integration with downstream clinical pipelines. Based on Deployment Model, the choice between Cloud Based and On Premise operations implicates governance, data residency, and cost structures, with hybrid approaches increasingly common to capture the benefits of both models.

Based on Therapeutic Area, the needs of cardiovascular, central nervous system, infectious diseases, and oncology programs vary in terms of target complexity, required assay validation, and tolerance for off-target liabilities. Oncology programs, for instance, often require sophisticated multi-omics integration and biomarker-driven validation, while infectious disease efforts may emphasize rapid screening and pathogen-specific constraint modeling. By mapping platform and application choices to end-user objectives and therapeutic constraints, organizations can more effectively prioritize investments and design fit-for-purpose workflows.

Regional capability patterns and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption pathways and partnership models

Regional context shapes how capabilities are adopted and scaled, influencing talent availability, regulatory expectations, and partnership ecosystems. In the Americas, there is a concentration of integrated biopharma organizations and a vibrant startup ecosystem that favors rapid prototyping, strong access to venture capital, and deep collaborations with clinical networks. These conditions support ambitious internal platforms and commercial partnerships, though they also require careful attention to IP strategy and compliance with evolving regulatory guidance.

In Europe, Middle East & Africa, the region presents a heterogeneous landscape where national research hubs and multinational centers of excellence coexist with growing public-private consortia. Regulatory harmonization efforts and strong emphasis on data protection influence preferred deployment models, often necessitating hybrid on-premise and cloud strategies that respect cross-border data transfer rules. Localized talent pools and strong academic links support method innovation, while strategic partnerships with contract research organizations help bridge scale and operational execution.

In the Asia-Pacific region, rapid expansion of computational capacity, strong government-backed initiatives, and a rising number of technology vendors are creating an environment conducive to large-scale adoption. This region often emphasizes cost-effective cloud solutions and regional data center investments, enabling high-throughput screening and model training at scale. However, differences in regulatory frameworks and language localization can introduce integration challenges, making regional partnerships and local compliance expertise critical for successful program deployment. Across all regions, organizations that align technical choices with local operational realities and partnership opportunities will achieve faster integration and greater resilience.

How differentiated technology capabilities, partnership models, and validation practices shape competitive positioning and long-term commercial relationships in computational discovery

Competitive dynamics in the in-silico drug discovery space are characterized less by single-vendor dominance and more by an ecosystem of specialized technology providers, platform integrators, and biopharma adopters forming modular value chains. Technology vendors differentiate through proprietary algorithms, curated training datasets, and the ability to integrate with laboratory automation and electronic laboratory notebook systems. Some firms emphasize physics-based simulation and molecular modeling, while others lead with generative chemistry and deep learning approaches, creating distinct value propositions for different stages of discovery.

Partnership archetypes include boutique technology providers collaborating with contract research organizations to offer end-to-end services, platform companies licensing core stacks to enterprise teams, and biopharma companies building internal centers of excellence that combine vendor solutions with in-house expertise. Strategic alliances between computational firms and large pharmaceutical organizations are common, and these relationships often center on co-development agreements, data-sharing frameworks, and joint validation studies that demonstrate translational relevance.

Additionally, service providers that can offer validated pipelines and regulatory-grade documentation gain preference among sponsors focused on clinical translation. The ability to demonstrate reproducibility, integrate with legacy IT systems, and meet stringent data governance requirements becomes a competitive differentiator. As a result, companies that invest in interoperability, transparent validation practices, and strong customer support tend to secure longer-term engagements and become preferred partners for enterprise-scale discovery initiatives.

Concrete strategic and operational priorities industry leaders must adopt to scale computational discovery from pilots to validated, production-grade drug discovery pipelines

Industry leaders should enact a coherent set of strategic and operational actions to convert computational promise into durable program outcomes. First, establish governance that ties computational objectives to therapeutic and portfolio goals, ensuring that model outputs feed directly into preclinical decision gates and that evaluation metrics are harmonized across teams. This alignment reduces friction when moving from pilot projects to production pipelines and clarifies investment priorities.

Second, invest in reproducibility and explainability. Embed version control for datasets and models, adopt standardized benchmarking protocols, and document workflows to support regulatory and audit requirements. These practices increase stakeholder confidence and reduce the risk of model drift or unintended biases affecting downstream experiments.

Third, architect flexible infrastructure. Adopt hybrid deployment patterns that allow for cloud elasticity during peak compute demands while preserving secure on-premise environments for sensitive data. Negotiate vendor contracts with clear service level agreements and redundancy provisions to mitigate supply chain disruptions and geopolitical risks.

Fourth, cultivate talent and cross-disciplinary collaboration. Build teams that combine computational scientists with medicinal chemists, pharmacologists, and regulatory experts to ensure that models are realistic, interpretable, and actionable. Provide continuous learning opportunities and create rotational programs that embed computational thinking across discovery functions.

Finally, pursue pragmatic partnerships and data strategies. Prioritize collaborations that provide curated, high-quality datasets with clear governance terms, and consider co-development agreements that share validation burdens. These steps accelerate time-to-impact while preserving strategic control over core IP and decision-critical datasets.

Transparent mixed-methods research protocol combining primary expert engagement, secondary literature synthesis, and multi-source data validation to ensure robust, actionable insights

The research approach underpinning this analysis combined qualitative expert engagement with structured secondary evidence synthesis and rigorous data validation protocols. Primary inputs were gathered through semi-structured interviews with domain experts spanning computational chemistry, machine learning, high-performance computing operations, and regulatory affairs, enabling direct insight into operational challenges, adoption barriers, and success factors observed in practice. These conversations were synthesized to surface common themes and divergent practices across organizational types.

Secondary evidence collection involved curated literature review of peer-reviewed methods papers, conference proceedings, technical white papers from technology providers, and publicly available regulatory guidance to triangulate claims and establish methodological baselines. Emphasis was placed on reproducibility and transparency, with methods and assumptions documented to permit independent review. Data validation employed cross-referencing across multiple independent sources, scenario testing to evaluate sensitivity to infrastructure and policy variables, and plausibility checks to ensure consistency with prevailing technology capabilities.

Limitations were acknowledged and addressed: primary interviews reflect experiential insights from a cross-section of organizations and are not exhaustive, and the pace of technological innovation means that specific tool capabilities evolve rapidly. To mitigate these constraints, the methodology prioritized durable patterns of behavior and structural dynamics over ephemeral product-level specifics. This mixed-methods design yields robust, actionable insights while making explicit the evidentiary basis for conclusions.

Consolidated conclusions emphasizing the necessity of governance, reproducibility, and deployment flexibility to realize sustained value from computational discovery programs

In conclusion, in-silico drug discovery is maturing into a strategic capability that requires deliberate organizational design, flexible infrastructure, and rigorous validation practices to deliver sustained translational value. The interplay of hybrid computational methods, evolving partnership models, and regional deployment realities creates both opportunities and operational complexities that leaders must navigate proactively. Those who align technical choices with therapeutic priorities, embed reproducibility and explainability into workflows, and pursue resilient procurement and deployment strategies will realize the greatest benefit.

Policy dynamics and supply chain pressures underscore the need for adaptable architectures and diversified vendor relationships, while segmentation-aware strategies ensure that investments map to the distinct needs of technology platforms, application types, end users, deployment models, and therapeutic areas. Ultimately, success depends on integrating computational insights into corporate decision-making processes and building cross-functional teams that can translate model outputs into decisive experimental actions. By treating in-silico discovery as a core competency rather than an auxiliary capability, organizations can accelerate the pathway from hypothesis to validated candidate while managing risk and preserving strategic optionality.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Silico Drug Discovery Market, by Technology Platform

  • 8.1. Computational Chemistry & Bioinformatics
  • 8.2. High Performance Computing
  • 8.3. Machine Learning & AI
  • 8.4. Molecular Modeling

9. In-Silico Drug Discovery Market, by Therapeutic Area

  • 9.1. Cardiovascular
  • 9.2. Central Nervous System
  • 9.3. Infectious Diseases
  • 9.4. Oncology

10. In-Silico Drug Discovery Market, by Molecule Modality

  • 10.1. Small Molecules
  • 10.2. Biologics
    • 10.2.1. Monoclonal Antibodies
    • 10.2.2. Bispecific Antibodies
  • 10.3. Peptides
    • 10.3.1. Linear Peptides
    • 10.3.2. Cyclic Peptides
  • 10.4. Oligonucleotides & RNA
    • 10.4.1. siRNA
    • 10.4.2. mRNA Therapeutics

11. In-Silico Drug Discovery Market, by Application

  • 11.1. ADMET Prediction
    • 11.1.1. Absorption Prediction
    • 11.1.2. Distribution Prediction
    • 11.1.3. Excretion Prediction
    • 11.1.4. Metabolism Prediction
    • 11.1.5. Toxicity Prediction
  • 11.2. Lead Identification & Optimization
    • 11.2.1. De Novo Design
    • 11.2.2. Fragment Based Optimization
  • 11.3. Pharmacokinetics Modeling
  • 11.4. Target Identification & Validation
  • 11.5. Virtual Screening
    • 11.5.1. Ligand Based Virtual Screening
    • 11.5.2. Structure Based Virtual Screening

12. In-Silico Drug Discovery Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Pharmaceutical & Biotechnology Companies

13. In-Silico Drug Discovery Market, by Deployment Model

  • 13.1. Cloud Based
  • 13.2. On Premise

14. In-Silico Drug Discovery Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. In-Silico Drug Discovery Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. In-Silico Drug Discovery Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States In-Silico Drug Discovery Market

18. China In-Silico Drug Discovery Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Charles River Laboratories International, Inc.
  • 19.6. Schrodinger Inc.
  • 19.7. Certara, Inc.
  • 19.8. XtalPi by Shenzhen Jingtai Technology Co., Ltd
  • 19.9. InSilico Medicine
  • 19.10. Dassault Systemes S.E.
  • 19.11. BenevolentAI
  • 19.12. Recursion Pharmaceuticals
  • 19.13. Evotec SE
  • 19.14. Iktos SA
  • 19.15. WuXi AppTec
  • 19.16. Envisagenics
  • 19.17. AbCellera Biologics Inc.
  • 19.18. Abzena Ltd.
  • 19.19. Aragen Life Sciences Pvt. Ltd.
  • 19.20. AstraZeneca PLC
  • 19.21. BioDuro LLC
  • 19.22. BioNTech SE
  • 19.23. Chemical Computing Group ULC
  • 19.24. ChemPartner PharmaTech Co Ltd
  • 19.25. Creative Biostructure
  • 19.26. Curia Global Inc.
  • 19.27. F. Hoffmann-La Roche Ltd.
  • 19.28. GenScript Biotech Corporation
  • 19.29. GlaxoSmithKline plc
  • 19.30. Ligand Pharmaceuticals Incorporated
  • 19.31. Merck & Co.
  • 19.32. Novartis AG
  • 19.33. Sanofi Group
  • 19.34. Selvita S.A.
  • 19.35. Simulations Plus, Inc.
  • 19.36. Sygnature Discovery
  • 19.37. Valo Health, Inc.
  • 19.38. Viva Biotech Holding Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY & BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY & BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY & BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING & AI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING & AI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING & AI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LINEAR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LINEAR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LINEAR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MRNA THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MRNA THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MRNA THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 244. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 246. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 250. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 251. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 253. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 255. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 283. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 285. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 286. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 290. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 292. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 293. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 294. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 296. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 298. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 299. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 303. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADME